{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:27:58Z","timestamp":1778232478870,"version":"3.51.4"},"reference-count":157,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ogc.2021.11.005","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T22:08:24Z","timestamp":1644617304000},"page":"117-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hereditary Breast and Ovarian Cancer"],"prefix":"10.1016","volume":"49","author":[{"given":"Cecelia A.","family":"Bellcross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ogc.2021.11.005_bib3","series-title":"The genetics of breast cancer","author":"Rubinstein","year":"2001"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited Mutations in Women With Ovarian Carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib6","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1002\/cphg.93","article-title":"Overview of Specifications to the ACMG\/AMP Variant Interpretation Guidelines","volume":"103","author":"Harrison","year":"2019","journal-title":"Curr Protoc Hum Genet"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/GCO.0b013e328332dca3","article-title":"BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications","volume":"22","author":"Kurian","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"44","key":"10.1016\/j.ogc.2021.11.005_bib8","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5182","key":"10.1016\/j.ogc.2021.11.005_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A\u00a0strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"6559","key":"10.1016\/j.ogc.2021.11.005_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-143-5-200509060-00012","article-title":"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force","volume":"143","author":"Nelson","year":"2005","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13073-019-0691-1","article-title":"Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank","volume":"12","author":"Abul-Husn","year":"2019","journal-title":"Genome Med"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","article-title":"Population genetic screening efficiently identifies carriers of autosomal dominant diseases","volume":"26","author":"Grzymski","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib14","doi-asserted-by":"crossref","first-page":"e182140","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome Sequencing-Based Screening for BRCA1\/2 Expected Pathogenic Variants Among Adult Biobank Participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10689-017-0038-2","article-title":"Mutations in context: implications of BRCA testing in diverse populations","volume":"17","author":"Felix","year":"2018","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-020-00819-1","article-title":"Family history assessment significantly enhances delivery of precision medicine in the genomics era","volume":"13","author":"Bylstra","year":"2021","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jgc4.1374","article-title":"Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors","volume":"30","author":"Berliner","year":"2021","journal-title":"J\u00a0Genet Couns"},{"issue":"7","key":"10.1016\/j.ogc.2021.11.005_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1245\/s10434-009-0697-9","article-title":"Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations","volume":"17","author":"Teller","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/GIM.0b013e3181d4bc3a","article-title":"Further development and evaluation of a breast\/ovarian cancer genetics referral screening tool","volume":"12","author":"Bellcross","year":"2010","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1548-5315(11)70263-7","article-title":"Approaches to applying breast cancer risk prediction models in clinical practice","volume":"8","author":"Bellcross","year":"2009","journal-title":"Comm Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41436-018-0020-x","article-title":"Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST)","volume":"21","author":"Bellcross","year":"2019","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.ogc.2021.11.005_bib24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jama.2019.8430","article-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.18.01631","article-title":"Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?","volume":"37","author":"Beitsch","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ogc.2021.11.005_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A\u00a0study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib29","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib30","first-page":"683731","article-title":"Universal Genetic Testing for All Breast Cancer Patients","volume":"33","author":"Copur","year":"2019","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41436-020-0862-x","article-title":"Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants","volume":"22","author":"Barnes","year":"2020","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.ogc.2021.11.005_bib32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jnci\/djaa040","article-title":"Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women","volume":"112","author":"Palmer","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"34","key":"10.1016\/j.ogc.2021.11.005_bib33","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jmedgenet-2017-105195","article-title":"Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population","volume":"55","author":"Manchanda","year":"2018","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/1940-6207.CAPR-20-0002","article-title":"Population-based Genetic Testing for Precision Prevention","volume":"13","author":"Evans","year":"2020","journal-title":"Cancer Prev Res (Phila)"},{"issue":"39","key":"10.1016\/j.ogc.2021.11.005_bib37","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib39","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"28","author":"Robson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ogc.2021.11.005_bib41","article-title":"Core Competencies in Cancer Genomics for Healthcare Professionals: Results From a Systematic Literature Review and a Delphi Process","author":"Hoxhaj","year":"2021","journal-title":"J\u00a0Cancer Educ"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4247-z","article-title":"Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications","volume":"164","author":"Cintolo-Gonzalez","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib43","doi-asserted-by":"crossref","first-page":"pky023","DOI":"10.1093\/jncics\/pky023","article-title":"Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study","volume":"2","author":"Schrijver","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.ogc.2021.11.005_bib45","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ajhg.2016.03.024","article-title":"Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium","volume":"98","author":"Amendola","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"34","key":"10.1016\/j.ogc.2021.11.005_bib47","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","article-title":"Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing","volume":"34","author":"Balmana","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.18632\/oncotarget.26501","article-title":"The effects of genomic germline variant reclassification on clinical cancer care","volume":"10","author":"Slavin","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/gim.2017.207","article-title":"Observed frequency and challenges of variant reclassification in a hereditary cancer clinic","volume":"20","author":"Macklin","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.ogc.2021.11.005_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.critrevonc.2018.09.009","article-title":"Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data","volume":"132","author":"van Marcke","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","article-title":"Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers","volume":"39","author":"Federici","year":"2020","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.ogc.2021.11.005_bib52","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/npjgenmed.2016.1","article-title":"Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance","volume":"1","author":"Woods","year":"2016","journal-title":"NPJ Genom Med"},{"issue":"11","key":"10.1016\/j.ogc.2021.11.005_bib53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jmedgenet-2017-104707","article-title":"DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment","volume":"54","author":"Toland","year":"2017","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41436-020-00991-0","article-title":"Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance","volume":"23","author":"Lyra","year":"2021","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA : J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","article-title":"Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","volume":"12","author":"Petrucelli","year":"2010","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.ogc.2021.11.005_bib57","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/gim.2018.44","article-title":"Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study","volume":"20","author":"Girardi","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome","volume":"7","author":"Samadder","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ogc.2021.11.005_bib59","first-page":"227","article-title":"Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes","volume":"13","author":"Peleg Hasson","year":"2020","journal-title":"Pharmgenomics Pers Med"},{"issue":"11\u201312","key":"10.1016\/j.ogc.2021.11.005_bib60","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00439-017-1845-0","article-title":"Expanding the spectrum of germline variants in cancer","volume":"136","author":"Siraj","year":"2017","journal-title":"Hum Genet"},{"issue":"23","key":"10.1016\/j.ogc.2021.11.005_bib61","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ogc.2021.11.005_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-017-0024-8","article-title":"The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk","volume":"3","author":"Slavin","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ogc.2021.11.005_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00217","article-title":"Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk","volume":"3","author":"Idos","year":"2019","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.ogc.2021.11.005_bib64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-020-0109-y","article-title":"Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes","volume":"4","author":"Landrith","year":"2020","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib65","doi-asserted-by":"crossref","first-page":"a036590","DOI":"10.1101\/cshperspect.a036590","article-title":"Tumor-Based Genetic Testing and Familial Cancer Risk","volume":"10","author":"Forman","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JOP.19.00201","article-title":"When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?","volume":"15","author":"DeLeonardis","year":"2019","journal-title":"J\u00a0Oncol Pract"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib67","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity","author":"Sokol","year":"2020","journal-title":"JCO Precision Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib68","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s13187-019-01535-0","article-title":"The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology","volume":"35","author":"McDaniels","year":"2020","journal-title":"J\u00a0Cancer Educ"},{"issue":"11","key":"10.1016\/j.ogc.2021.11.005_bib69","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa0907727","article-title":"Performance of common genetic variants in breast-cancer risk models","volume":"362","author":"Wacholder","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ogc.2021.11.005_bib70","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/gim.2018.38","article-title":"False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care","volume":"20","author":"Tandy-Connor","year":"2018","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.ogc.2021.11.005_bib71","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib72","doi-asserted-by":"crossref","first-page":"pkaa029","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1\/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","article-title":"Polygenic risk scores: from research tools to clinical instruments","volume":"12","author":"Lewis","year":"2020","journal-title":"Genome Med"},{"issue":"R2","key":"10.1016\/j.ogc.2021.11.005_bib74","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1093\/hmg\/ddz205","article-title":"Validity of polygenic risk scores: are we measuring what we think we are?","volume":"28","author":"Janssens","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib75","first-page":"327","article-title":"Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine","volume":"61","author":"Weitzel","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.ogc.2021.11.005_bib76","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/annonc\/mdn527","article-title":"Age of onset in familial cancer","volume":"19","author":"Brandt","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib77","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/GIM.0b013e3181837246","article-title":"Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians","volume":"10","author":"Lowstuter","year":"2008","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cge.12868","article-title":"Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review","volume":"92","author":"Willis","year":"2017","journal-title":"Clin Genet"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10897-016-0040-0","article-title":"Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter","volume":"26","author":"Kne","year":"2017","journal-title":"J\u00a0Genet Couns"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib80","first-page":"495","article-title":"GINA at 10 years: the battle over 'genetic information' continues in court","volume":"5","author":"Suter","year":"2018","journal-title":"J\u00a0L Biosci"},{"key":"10.1016\/j.ogc.2021.11.005_bib81","first-page":"1","article-title":"The Affordable Care Act's pre-existing condition insurance plan: enrollment, costs, and lessons for reform","volume":"24","author":"Hall","year":"2012","journal-title":"Issue Brief (Commonw Fund)"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib82","first-page":"3647","article-title":"Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature","volume":"27","author":"Lombardi","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib83","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1037\/a0014778","article-title":"Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review","volume":"28","author":"Hamilton","year":"2009","journal-title":"Health Psychol"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib84","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s10897-016-9949-6","article-title":"Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1\/2 Mutation Carriers: a Systematic Review","volume":"25","author":"Ringwald","year":"2016","journal-title":"J\u00a0Genet Couns"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cancergencyto.2005.07.011","article-title":"Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families","volume":"165","author":"Lynch","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"23","key":"10.1016\/j.ogc.2021.11.005_bib86","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib87","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2005.03.6772","article-title":"Characterization of BRCA1 and BRCA2 mutations in a large United States sample","volume":"24","author":"Chen","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib88","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.2007.55-a","article-title":"Variation of breast cancer risk among BRCA1\/2 carriers","volume":"299","author":"Begg","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib89","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","article-title":"Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers","volume":"46","author":"Evans","year":"2009","journal-title":"J\u00a0Med Genet"},{"issue":"11","key":"10.1016\/j.ogc.2021.11.005_bib90","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib91","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"104","author":"Metcalfe","year":"2011","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib92","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10549-015-3419-y","article-title":"Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry","volume":"151","author":"Menes","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib93","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-019-05162-7","article-title":"Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers","volume":"175","author":"Kotsopoulos","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","article-title":"Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age","volume":"124","author":"van der Kolk","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib95","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1055-9965.EPI-14-0532","article-title":"Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"24","author":"Peterlongo","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib96","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/ERC-16-0277","article-title":"Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers","volume":"23","author":"Milne","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ogc.2021.11.005_bib97","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2018.00490","article-title":"GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers","volume":"8","author":"Lesueur","year":"2018","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.ogc.2021.11.005_bib98","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jnci\/djq443","article-title":"Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations","volume":"102","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib99","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10897-016-0049-4","article-title":"Lifestyle Risk Factors for Breast Cancer in BRCA1\/2-Mutation Carriers Around Childbearing Age","volume":"26","author":"van Erkelens","year":"2017","journal-title":"J\u00a0Genet Couns"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","article-title":"Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review","volume":"301","author":"Huber","year":"2020","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib101","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ogc.2021.11.005_bib102","doi-asserted-by":"crossref","first-page":"531790","DOI":"10.3389\/fonc.2020.531790","article-title":"Pathology of Hereditary Breast and Ovarian Cancer","volume":"10","author":"Hodgson","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib104","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/CCO.0b013e3283499da9","article-title":"Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies","volume":"23","author":"Long","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib106","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.5145","article-title":"Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas","volume":"246","author":"Soong","year":"2018","journal-title":"J\u00a0Pathol"},{"issue":"40","key":"10.1016\/j.ogc.2021.11.005_bib107","doi-asserted-by":"crossref","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"43","key":"10.1016\/j.ogc.2021.11.005_bib108","doi-asserted-by":"crossref","first-page":"70113","DOI":"10.18632\/oncotarget.12158","article-title":"BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib109","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ogc.2021.11.005_bib110","first-page":"8545643","article-title":"Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis","volume":"2020","author":"Pogoda","year":"2020","journal-title":"J\u00a0Oncol"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib111","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers11060738","article-title":"Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1\/BRCA2 Mutation Carriers Versus Non-Carriers","volume":"11","author":"Vocka","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ogc.2021.11.005_bib112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41523-020-00185-6","article-title":"Association of germline variation with the survival of women with BRCA1\/2 pathogenic variants and breast cancer","volume":"6","author":"Muranen","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib113","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.ogc.2021.11.005_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13053-015-0044-z","article-title":"Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients","volume":"14","author":"Synowiec","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.ogc.2021.11.005_bib116","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-14-3242","article-title":"Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy","volume":"75","author":"Chen","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib117","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10689-016-9873-9","article-title":"Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis","volume":"15","author":"Sabatier","year":"2016","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib118","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib119","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2019.02.022","article-title":"National Israeli Study of Ovarian C. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1\/2 mutations - the National Israeli Study of Ovarian Cancer","volume":"153","author":"Lavie","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib121","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1245\/s10434-012-2299-1","article-title":"Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients","volume":"19","author":"Chung","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib122","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1245\/s10434-016-5328-7","article-title":"Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for brca1\/brca2 mutation carriers with breast cancer","volume":"23","author":"Chiba","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib123","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.clbc.2021.01.008","article-title":"Influential factors on risk reduction mastectomy in a high-risk breast cancer population with genetic predispositions","volume":"21","author":"Wei","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib124","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/jamasurg.2020.6254","article-title":"American society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline for management of hereditary breast cancer","volume":"156","author":"Yip","year":"2021","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib125","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.mayocp.2019.02.017","article-title":"Hereditary cancer syndromesda primer on diagnosis and management, part 1: breast-ovarian cancer syndromes","volume":"94","author":"Samadder","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"26","key":"10.1016\/j.ogc.2021.11.005_bib126","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ogc.2021.11.005_bib127","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.2147\/CMAR.S194874","article-title":"First-line treatment with olaparib for early stage brca-positive ovarian cancer: may it be possible? hypothesis potentially generating a line of research","volume":"12","author":"Tomao","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib128","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/cncr.27864","article-title":"Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers","volume":"119","author":"Cott Chubiz","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib129","first-page":"75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"10.1016\/j.ogc.2021.11.005_bib130","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ogc.2021.11.005_bib132","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib133","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1245\/s10434-015-4532-1","article-title":"Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"22","author":"De Felice","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2021.11.005_bib134","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4476-1","article-title":"The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy","volume":"167","author":"Giannakeas","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib136","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","article-title":"Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?","volume":"145","author":"McGee","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib137","volume":"78","author":"Phillips","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ogc.2021.11.005_bib138","first-page":"1","article-title":"Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers","author":"Singer","year":"2021","journal-title":"Breast Care"},{"issue":"21","key":"10.1016\/j.ogc.2021.11.005_bib139","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ogc.2021.11.005_bib140","doi-asserted-by":"crossref","first-page":"e023115","DOI":"10.1136\/bmjopen-2018-023115","article-title":"Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment","volume":"8","author":"Campbell","year":"2018","journal-title":"BMJ Open"},{"issue":"15_suppl","key":"10.1016\/j.ogc.2021.11.005_bib141","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2020.38.15_suppl.1534","article-title":"Five year letrozole versus placebo in BRCA1\/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial","volume":"38","author":"Pujol","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ogc.2021.11.005_bib142","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1471-0528.2007.01499.x","article-title":"Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective","volume":"114","author":"Woodward","year":"2007","journal-title":"BJOG : Int J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib143","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","article-title":"Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers?","volume":"124","author":"van der Velde","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ogc.2021.11.005_bib144","first-page":"CD012464","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ogc.2021.11.005_bib145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.ogc.2021.11.005_bib146","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib147","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.clbc.2018.09.011","article-title":"Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review","volume":"19","author":"Xiao","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ogc.2021.11.005_bib148","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.ogc.2021.11.005_bib149","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/medicina55080415","article-title":"Risk-reducing bilateral salpingo-oophorectomy for brca mutation carriers and hormonal replacement therapy: if it should rain, better a drizzle than a storm","volume":"55","author":"Gasparri","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"23","key":"10.1016\/j.ogc.2021.11.005_bib150","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","article-title":"Breast cancer risk among male BRCA1 and BRCA2 mutation carriers","volume":"99","author":"Tai","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib151","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ogc.2021.11.005_bib152","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-019-05429-z","article-title":"Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing","volume":"178","author":"Scarpitta","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib153","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-018-4661-x","article-title":"Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer","volume":"169","author":"Fostira","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"30","key":"10.1016\/j.ogc.2021.11.005_bib154","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ogc.2021.11.005_bib155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/EDBK_238977","article-title":"The role of BRCA testing in hereditary pancreatic and prostate cancer families","volume":"39","author":"Pilarski","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib156","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaoncol.2019.5963","article-title":"An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review","volume":"6","author":"Rainone","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ogc.2021.11.005_bib157","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ogc.2021.11.005_bib158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ogc.2021.11.005_bib159","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2021.11.005_bib160","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/CMR.0000000000000613","article-title":"Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma","volume":"29","author":"Johansson","year":"2019","journal-title":"Melanoma Res"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854521007737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854521007737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:25:25Z","timestamp":1760178325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854521007737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0889854521007737"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2021.11.005","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary Breast and Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}